Study deep dives
Landmark studies, in depth
The peptide profiles summarise each compound's evidence base in a paragraph or two. These deep dives unpack the most-cited individual studies and clinical-trial programmes in detail — what they measured, what they showed, and where the methodological limits sit.
The Semax stroke-rehabilitation trial programme — what the Russian post-stroke evidence actually shows
The strongest single-peptide clinical evidence base in the cognitive-peptide field is the body of Russian post-stroke rehabilitation work with Semax. This article unpacks what the trials actually measured, what they showed, and what the methodological limits are.
Read the breakdownThe Dihexa spinogenesis breakthrough — what the picomolar dendritic-spine data actually shows
The Joseph Harding group's Dihexa research demonstrated dendritic spine formation at picomolar concentrations — orders of magnitude beyond BDNF on the same assay. This article explains what was measured, why the result matters, and why the compound nonetheless remains preclinical.
Read the breakdownSelank vs benzodiazepines — what the comparative anxiolytic trials show
Selank's most-cited clinical evidence is its head-to-head comparison with benzodiazepine anxiolytics in generalised anxiety populations. This article unpacks what the trials measured, how Selank performed relative to the benzodiazepine standard, and what differential side-effect profile emerged.
Read the breakdownThe Cerebrolysin vascular-dementia evidence — what the systematic reviews actually find
Cerebrolysin has the largest randomised-trial body of any cognitive peptide. This article walks through the vascular-dementia meta-analytic record, what the pooled effect sizes show, and why the compound remains unlicensed in the UK despite the evidence base.
Read the breakdownNoopept in mild cognitive impairment — what the Russian clinical-trial record shows
Noopept's clinical-trial body in mild cognitive impairment is the principal clinical evidence supporting the compound's 2011 Russian regulatory approval. This article walks through what the trials measured, what they showed, and how the evidence compares with other cognitive-peptide records.
Read the breakdown